Immune checkpoint inhibitors, such as anti-PD-1 (programmed cell death protein 1) and anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) antibodies, work by blocking the checkpoints that cancer cells use to evade immune detection (99). This evidence concerns the gene CTLA4 and cancer.